<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03322436</url>
  </required_header>
  <id_info>
    <org_study_id>ST0083</org_study_id>
    <nct_id>NCT03322436</nct_id>
  </id_info>
  <brief_title>HeartLinc, a Study With AMI Patients Undergoing PCI</brief_title>
  <acronym>HeartLinc</acronym>
  <official_title>A Non-interventional Patient Study to Demonstrate Medical Utility of the lncRNA to Predict HF in AMI Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Firalis SA</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Firalis SA</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      HeartLinc is a non-interventional patient study to demonstrate medical utility of the lncRNA&#xD;
      to predict HF in AMI patients. 300 patients are expected to be recruited.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The recruiting phase of the study includes the recruitment of patients (36 months) and is&#xD;
      followed by 12 month of monitoring for each patient. After deciding MI and PCI treatment by&#xD;
      physical exam, ECG and other diagnostic methods, blood samples will be collected. After&#xD;
      undergoing PCI, samples of the same patients will be collected during hospitalization days&#xD;
      after PCI (D0-3) according to the patient study flowchart. After hospitalization, patients&#xD;
      will be contacted by phone call or written questionary after 30 days (D30). After 6 and 12&#xD;
      months, patients are reinvited for a routine rehospitalisation to perform clinical exams and&#xD;
      ECGs. Blood and urine samples will be collected after 12 months.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">March 13, 2018</start_date>
  <completion_date type="Anticipated">December 3, 2022</completion_date>
  <primary_completion_date type="Anticipated">July 31, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>LV-EF &lt; 40%</measure>
    <time_frame>12 months</time_frame>
    <description>Proportion of patients with LV-EF &lt; 40% at 12 months measured by echocardiography</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>LVEDV</measure>
    <time_frame>12 months</time_frame>
    <description>Left Ventricular End Diastolic Volume (LVEDV) at 12 months</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">240</enrollment>
  <condition>AMI Patients</condition>
  <arm_group>
    <arm_group_label>AMI patients treated by PCI</arm_group_label>
    <description>AMI patient treated by PCI at risk to develop Heart Failure</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>HeartLinc kit</intervention_name>
    <description>Samples are collected and analyzed afterwards</description>
    <arm_group_label>AMI patients treated by PCI</arm_group_label>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Blood and urine samples&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        AMI patients undergoing PCI&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients over 18 years&#xD;
&#xD;
          -  Myocardial infarction in association with a recent acute coronary syndrome &lt;24 hrs&#xD;
             leading to a coronary angioplasty decision&#xD;
&#xD;
          -  Myocardial infarction with ST-elevation (STEMI) or myocardial infarction following&#xD;
             acute coronary syndrome without ST-segment shift with a significant elevation of&#xD;
             non-ST troponin (NSTEMI)&#xD;
&#xD;
          -  Participation in the Hearlink Cohort&#xD;
&#xD;
          -  Collecting and signed informed consent for Heartlink study participation and consent&#xD;
             to participate in the ancillary Heartlink 2 study&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Sudden Cardiac arrest which resulted in resuscitation other than single, non-repeated&#xD;
             electric shock,&#xD;
&#xD;
          -  cardiogenic shock&#xD;
&#xD;
          -  Severe extra-cardiac diseases involving the short-term life expectancy of patients&#xD;
             (risk of death at one year&#xD;
&#xD;
          -  Programmed major non-cardiac surgery&#xD;
&#xD;
          -  Known Altered Left Ventricular function before Acute Coronary Syndrome inclusion&#xD;
&#xD;
          -  History of left, right or global heart failure&#xD;
&#xD;
          -  Significant heart failure at hospital admittance (KILLIP 2)&#xD;
&#xD;
          -  Acute Coronary Syndrome know more than 24 hours&#xD;
&#xD;
          -  History of Myocardial infarction&#xD;
&#xD;
          -  Participation in any other in progress or stopped study for less than 3 months other&#xD;
             than the Heartlink study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>HÃ¼seyin FIRAT, MD, PhD,</last_name>
    <role>Principal Investigator</role>
    <affiliation>Firalis SA</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>CHU de TOULOUSE</name>
      <address>
        <city>Toulouse</city>
        <zip>31059</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SNUH</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>October 24, 2017</study_first_submitted>
  <study_first_submitted_qc>October 25, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">October 26, 2017</study_first_posted>
  <last_update_submitted>August 9, 2021</last_update_submitted>
  <last_update_submitted_qc>August 9, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 10, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

